Imprimis Pharmaceuticals Stock Forecast

Buy or Hold candidate since Jun 10, 2026 Gain 29.94%

The Imprimis Pharmaceuticals stock price gained 3.94% on the last trading day (Friday, 17th Jul 2026), rising from $44.88 to $46.65. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 7.87% from a day low at $44.04 to a day high of $47.50. The price has been going up and down for this period, and there has been a 9.15% gain for the last 2 weeks. Volume fell on the last day by -102 thousand shares and in total, 813 thousand shares were bought and sold for approximately $37.93 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the upper part of a very wide and strong rising trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break-up at the top trend line at $47.79 will firstly indicate a stronger rate of rising. Given the current short-term trend, the stock is expected to rise 17.00% during the next 3 months and, with a 90% probability hold a price between $39.96 and $55.91 at the end of this 3-month period.

HROW Signals & Forecast

The Imprimis Pharmaceuticals stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $43.29 and $39.96. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Tuesday, May 12, 2026, and so far it has risen 60.70%. Further rise is indicated until a new top pivot has been found. Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Imprimis Pharmaceuticals stock

On the downside, the stock finds support just below today's level from accumulated volume at $42.78 and $42.07. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Imprimis Pharmaceuticals finds support just below today's level at $42.78. If this is broken, then the next support from accumulated volume will be at $42.07 and $35.90.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $3.47 between high and low, or 7.87%. For the last week, the stock has had daily average volatility of 5.46%.

Our recommended stop-loss: $45.15 (-3.22%) (This stock has medium daily movements and this gives medium risk. There is a buy signal from a pivot bottom found 45 days ago.)

Trading Expectations (HROW) For The Upcoming Trading Day Of Monday 20th

For the upcoming trading day on Monday, 20th we expect Imprimis Pharmaceuticals to open at $46.06, and during the day (based on 14 day Average True Range), to move between $45.53 and $47.77, which gives a possible trading interval of +/-$2.25 (+/-4.94%) up or down from last closing price. If Imprimis Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 4.94% move between the lowest and the highest trading price during the day.

With no resistance above and support from accumulated volume @ $42.78, some $3.87 (8.30%) from the current price of $46.65, our system finds the risk reward attractive.

Is Imprimis Pharmaceuticals stock A Buy?

Imprimis Pharmaceuticals holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months. We have upgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Strong Buy candidate.

Current score: 6.278 Strong Buy Candidate Upgraded

Predicted Fair Opening Price

Predicted fair opening price on July 20, 2026 - $46.06 ( 1.26%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk